AstraZeneca PLC / Quell Therapeutics Limited

Type 1 Diabetes (engineered Treg cell therapy)

1.9M US cases/yr · $22.0B Global T1D therapeutics market (insulin + immunomodulatory + cell-therapy, 2023) · ~$2.1B AstraZeneca total deal value ($85M upfront + >$2B in milestones)

Disease Overview

Type 1 diabetes (T1D) is a chronic autoimmune disease in which autoreactive CD4 and CD8 T cells destroy insulin-producing pancreatic beta cells, producing absolute insulin deficiency and lifelong dependence on exogenous insulin. The CDC estimates approximately 1.9 million US adults and ~304,000 US children and adolescents live with T1D, with roughly 64,000 new diagnoses annually across all ages. Global T1D prevalence is approximately 9 million. Despite closed-loop insulin pumps, CGM, and teplizumab (Tzield, Sanofi/Provention, approved November 2022 to delay Stage-3 T1D in Stage-2 patients), the disease retains substantial unmet need: patients face chronic hypoglycemia risk, lifelong glycemic variability, and elevated cardiovascular, renal, retinal, and neurologic complications. Recent approvals of allogeneic islet-cell therapy donislecel (Lantidra, CellTrans, June 2023) and the maturation of Vertex VX-880/zimislecel signal a shift toward disease-modifying and potentially curative approaches. Engineered regulatory-T-cell (Treg) therapies aim to restore immune tolerance to pancreatic beta cells, stopping ongoing autoimmune destruction without global immunosuppression and without islet replacement.

Competitive Landscape

The T1D disease-modification landscape has matured meaningfully. Sanofi/Provention's teplizumab (Tzield) became in November 2022 the first FDA-approved therapy to delay Stage 3 T1D in Stage 2 patients, establishing the anti-CD3 immunomodulatory precedent. Cell-replacement strategies include Vertex VX-880/zimislecel (allogeneic stem-cell-derived islet cells, Phase 1/2/3 with durable insulin independence), VX-264 (encapsulated, immunosuppression-free, Phase 1/2), CellTrans donislecel (Lantidra, approved 2023 for brittle T1D), and Sernova Cell Pouch. In Treg cell therapy specifically, direct competitors to Quell's QEL-001/QEL-101 include: Sonoma Biotherapeutics SBT-77-7101 (Tregs for T1D, Phase 1); Coya Therapeutics COYA 301 (low-dose IL-2 Treg expansion, Phase 2 ALS); Kyverna KYV-101 (CD19 CAR-T, autoimmune); Cabaletta CABA-201 (CD19 CAR-T); and academic programs including Caladrius CLBS03 (Phase 2 T1D Tregs, discontinued). In IBD, competing mechanisms include TL1A (tulisokibart), IL-23 (risankizumab Skyrizi, mirikizumab Omvoh), alpha-4/beta-7 (vedolizumab Entyvio), S1P (ozanimod Zeposia, etrasimod Velsipity), and JAK (upadacitinib Rinvoq, tofacitinib Xeljanz). Quell's engineered multi-modular Treg platform (TCR + safety switches + CAR add-ons) differentiates by building antigen-specific tolerance rather than global immunosuppression.